CENTERVILLE, MA -- (Marketwire) -- 06/02/11 -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the 'Company') is pleased to announce it has hired Denny Mulloy to assume the role of Executive Vice President of Sales, Marketing and Alliances for UV Flu, and its wholly owned subsidiary, Rx Air.
Mr. Mulloy has a long and distinguished career in various senior Sales and Marketing positions, with over 40 years experience with Fortune 100 companies such as NCR, Xerox, Dun and Bradstreet and I2 Technologies. During the course of his career, he was named the number one salesperson at both Xerox and Dun and Bradstreet Software. He has been serving as Chief Operating Partner for Blue Green Partners, a green technology and services company located in Dallas, Texas.
'We are thrilled to have someone of Denny's caliber join us,' said Jack Lennon, President of UV Flu. 'Over the last 6 months, we have purchased RX Air, paid off almost all our debt, added numerous distributors, domestically and internationally, refocused our entire marketing approach, while also rebranding our marketing materials. Denny's addition will enable us to efficiently address our newly created demand and growth opportunities. His focus on the Sales, Marketing and Alliances function will enable us to compress our timeline for the pending international distribution agreements, as well as additional domestic distributors. This strategic decision will accelerate our new product development, and enhancement plans.'
'Seldom have I encountered an opportunity as ripe for growth as I see with UV Flu and RX Air,' said Denny Mulloy, new Executive Vice President of Sales for UV Flu and RX Air. 'This entire space is poised for growth, with much larger growth potential than what one would have seen 30 years ago before bottled water became popular. There is nothing more important to human health than the quality of the air we breathe 24 hours per day, but there is almost no attention or education being devoted to the sector. We are going to change this.'
'The global impact to personal well being, and escalating health care costs are directly attributable to the significant rise in asthma, allergies, respiratory issues, and drug-resistant viruses. We're excited about the opportunity to enable people to live longer, healthier, and more productive lives, through the use of our proven, cost effective solutions. We're also confident of our ability to capture a healthy percentage, of what we think will become a $10 billion a year market over the next 5 years,' said Mr. Mulloy.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ('SEC') EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ('IAQ') industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UVFlu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.
Notice Regarding Forward-Looking Statements
This news release contains 'forward-looking statements' as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO